Huntsville, Alabama, USA
We plan to invest more than US$6 billion in a next-generation manufacturing site focused on small molecule synthetic and peptide medicines across various therapeutic areas.
Katwijk, Netherlands
This US$3 billion investment will enhance our supply chain resilience and expand manufacturing capacity for our oral medicines across key therapeutic areas.
Carolina, Puerto Rico, USA
A US$1.2 billion investment will expand and modernise our existing site, integrating advanced technologies and automation to support the reliable supply of high-quality oral medicines.
Houston, Texas, USA
We plan to invest more than US$6.5 billion in a new site that will focus on manufacturing small molecule synthetic medicines across our focus areas of cardiometabolic health, oncology, immunology and neuroscience.
Goochland County, Virginia, USA
Read more details about the new Virginia site.
Kenosha County, Wisconsin, USA
We announced a US$3 billion expansion of the injectable manufacturing facility which we acquired in April 2024 in Kenosha County, Wisconsin, to support the increased demand for Lilly medicines. The acquisition, expansion and additional purchases of land and the adjacent warehouse bring our total planned investment in Wisconsin to US$4 billion—the single largest U.S. manufacturing investment outside of our home state of Indiana. Medicine production at the existing state-of-the-art facility and the construction of the expansion are both planned to begin in 2025.
Read about the Kenosha County facility acquisition.
Read about the US$3 billion expansion of the Kenosha County facility.
Limerick and Kinsale, Ireland
Our Kinsale site employs a digital-first process that integrates continuous manufacturing technology to create a new manufacturing platform for complex peptides. An additional US$800 million expansion to Kinsale’s pivotal site will help meet the demand and maintain a reliable supply of Lilly’s diabetes and obesity medicines.
Read about the US$1 billion expansion of the Limerick site.
Lebanon, Indiana, USA
Our total investment in manufacturing facilities in Lebanon is US$9 billion. This is the single largest investment in active pharmaceutical ingredient (API) manufacturing of synthetic medicines in U.S. history. In addition to delivering next-generation therapeutic modalities, including genetic medicines, we will boost production of API at this site.
Read about the US$9 billion investment in the Lebanon, Indiana, manufacturing facility.
Research Triangle Park and Concord, North Carolina, USA
Read about the Research Triangle Park expansion.
Read about the Concord investment.
Alzey, Germany
A US$2.5 billion high-tech manufacturing site in Alzey, Rhineland-Palatinate, Germany. This new facility will further expand the company’s global product and device manufacturing network.